PUBLIC COMPANY
save$LBRXLB PHARMACEUTICALS INC
$LBRX36.99-0.78%New York, NY, USupdated 1d ago
community read0 votes
pipeline
3
marketed
1
phase 3
1
catalysts ytd
7
approvals ytd
0
recalls ytd
5
Pipeline(3)
pipeline depth3 products
1Preclinical1Phase 31Marketed
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase2Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.
- phase352-week Open Label Safety-Tolerability Study
- phase3Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
- phase2Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia
🐶 Hiring Signal
News
- Chutes & Ladders—Legend poaches Novartis vet to boost commercial potentialAfter former Legend Biotech CEO Ying Huang, Ph.D., left the company suddenly in July, Legend has found its permanent CEO, poaching Novartis veteran Ingrid Zhang as the CAR-T specialist eyes its nex…fiercebiotech · 16d ago
- Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, which could make the sector more broadly appealing to investors, some say.biopharma_dive · 5mo ago
Data sources
last refreshed 39m ago
Found something off?
comments(0)
5-min edit window · permanent after that